<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635971</url>
  </required_header>
  <id_info>
    <org_study_id>TAI-2015</org_study_id>
    <nct_id>NCT02635971</nct_id>
  </id_info>
  <brief_title>Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>A Randomized Controlled Phase II Study on Intra-arterial Versus Intravenous Chemotherapy Infusion With Gemcitabine and Oxaliplatin for Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the efficacy and safety of intra- arterial infusion of gemcitabine&#xD;
      and oxaliplatin in locally advanced pancreatic cancer. This protocol is overseen by the Fudan&#xD;
      University Institutional Review Board which has Federal Wide Assurance through the U.S.&#xD;
      Department of Health &amp; Human Services (Approved: April 25, 2002).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Outcome Measures:&#xD;
&#xD;
      To compare the overall survival (OS) in patients with locally advanced pancreatic cancer&#xD;
      treated with transcatheter arterial infusion (TAI) of chemotherapeutics or systemic delivered&#xD;
      chemotherapy.&#xD;
&#xD;
      Secondary Outcome Measures:&#xD;
&#xD;
      To compare the progression free survival (PFS), objective response rate (ORR), quality of&#xD;
      life (QoL), and adverse effects of treating locally advanced pancreatic cancer patients with&#xD;
      TAI or systemic chemotherapy.&#xD;
&#xD;
      Exploratory Outcome Measures:&#xD;
&#xD;
      To evaluate the correlation between prognosis and expression of serum microRNAs of the&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization until the date of death, assessed up to 100 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Carcinoma, Pancreatic</condition>
  <arm_group>
    <arm_group_label>TAI chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive transcatheter arterial infusion of chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive intravenous chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter arterial infusion</intervention_name>
    <arm_group_label>TAI chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravenous chemotherapy</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>TAI chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>TAI chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/cytologically confirmed unresectable locally advanced pancreatic&#xD;
             adenocarcinoma.&#xD;
&#xD;
          -  Measurable disease by RECIST criteria must be present.&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 70&#xD;
&#xD;
          -  Patients with adequate organ functions reflected by the laboratory criteria below:&#xD;
&#xD;
        Granulocytes ≥ 1,500/uL Hemoglobin ≥ 8.0 gm/dL Platelets ≥ 100,000/uL Serum creatinine &lt;&#xD;
        2.0 mg/dL Bilirubin &lt; 1.5 mg/dL SGPT &lt; 2.5 x normal Alk Phos &lt; 2.5 x normal&#xD;
&#xD;
          -  Prior local therapy, e.g., radiation, is allowed provided that at least 4 weeks&#xD;
             washout time is given.&#xD;
&#xD;
          -  Patients with jaundice must have a biliary drainage decompression operation before&#xD;
             recruitment.&#xD;
&#xD;
          -  Patients must not be pregnant. Serum beta-HCG will be checked in all premenopausal&#xD;
             patients.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with metastatic disease.&#xD;
&#xD;
          -  Prior treatment with systemic chemotherapy.&#xD;
&#xD;
          -  Known allergies to the gemcitabine, oxaliplatin or iodine contrast agent.&#xD;
&#xD;
          -  Subject with Child-Pugh grade Class C hepatic impairment, active gastrointestinal&#xD;
             bleeding, severe coagulation disorder that could not be corrected，or other&#xD;
             contraindication for transcatheter infusion.&#xD;
&#xD;
          -  Untreated or uncontrolled deep vein thrombosis, arterial thrombosis of lower&#xD;
             extremity, or aneurysm.&#xD;
&#xD;
          -  Concurrent infection requiring intravenous antibiotics.&#xD;
&#xD;
          -  Skin injury or infection of groin area, or other situation that not appropriate for&#xD;
             femoral artery puncture.&#xD;
&#xD;
          -  Other serious illness or condition including cardiac disease including congestive&#xD;
             heart failure (New York Heart Association Classification III or IV), active HIV&#xD;
             infection/HIV disease, psychiatric disorders.&#xD;
&#xD;
          -  Known central nervous system involvement and leptomeningeal disease&#xD;
&#xD;
          -  Subject with previous or concurrent cancer that is distinct in primary site or&#xD;
             histology from pancreatic adenocarcinoma except cervical carcinoma in situ,&#xD;
             non-melanoma carcinoma of the skin or in situ carcinoma of the bladder. Any cancer&#xD;
             curatively treated greater than 3 years prior to entry is permitted.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiqiang Meng, MD, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yehua Shen, MD, Ph D</last_name>
    <phone>86-21-64175590</phone>
    <phone_ext>83625</phone_ext>
    <email>yehuash25@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yehua Shen, MD, Ph D</last_name>
      <phone>86-21-64175590</phone>
      <phone_ext>83625</phone_ext>
      <email>yehuash25@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhiqiang Meng, MD, Ph D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yehua Shen, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhiqiang Meng</investigator_full_name>
    <investigator_title>Professor, MD, Ph D</investigator_title>
  </responsible_party>
  <keyword>transcatheter arterial infusion</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>chemotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

